Armata Pharmaceuticals- Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient

Armata’s bacteriophage, AP-PA01, used to treat multidrug-resistant Pseudomonas aeruginosa infection

Paper appears in the peer-reviewed journal Infection. Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the publication of a case study involving a cystic fibrosis patient who was successfully treated for a multidrug-resistant Pseudomonas aeruginosa infection with the Company’s natural phage product, AP-PA01. The paper, entitled “Successful adjunctive use of bacteriophage therapy for treatment of multidrug‑resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient,” appears in the peer-reviewed journal Infection. In addition to its work with AP-PA01, Armata is engineering its Pseudomonas aeruginosa phage to create a new, synthetic phage product, AP-PA02. 

Unknown's avatar

Published by Dr. Prasanth Manohar, Ph.D.,

Early career researcher in the field of Microbiology. Phage biologist, Author, Editor and Scientific writer. Expertise is in bacteriophage biology & genetics, Phage Therapy, ssRNA phages, Phage lysis systems, Single-cell analysis, protein antibiotics, and Antibiotic Resistance.